New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:39 EDTCELGCelgene reinstated with a Buy at BofA/Merrill
Target $112.
September 29, 2014
08:55 EDTCELGCelgene price target raised to $115 from $100 at RBC Capital
RBC Capital increased its price target on Celgene (CELG) as the firm now estimates that the company's new oral Crohn's disease drug GED-0301 will generate $1B in sales. The firm expects Celgene's stock to rise further as it predicts that Phase II data for the company's Crohn's treatment will be much better than the data for AbbVie's (ABBV) Crohn's treatment, Humira. RBC predicts that Celgene's long-term 2020 guidance will beat expectations if the company is able to reach a legal settlement with Actavis (ACT.). RBC Capital keeps an Outperform rating on Celgene.
07:26 EDTCELGInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
09:36 EDTCELGActive equity options trading on open
Subscribe for More Information
September 24, 2014
13:17 EDTCELGCelgene continues rally after FDA approval of psoriasis drug
Subscribe for More Information
07:01 EDTCELGCelgene OTEZLA to become important revenue generator, says Cantor
Subscribe for More Information
September 23, 2014
15:21 EDTCELGCelgene announces FDA approves Otezla for treating plaque psoriasis
Subscribe for More Information
September 22, 2014
07:21 EDTCELGEBD Group to hold a conference
Subscribe for More Information
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use